deltatrials

Cambridge University Hospitals NHS Foundation Trust Clinical Trials

Sponsors / Cambridge University Hospitals NHS Foundation Trust

Cambridge University Hospitals NHS Foundation Trust is listed as the lead sponsor on 221 clinical trials registered with ClinicalTrials.gov. Across the portfolio, 28 are in recruitment, 12 are active non-recruiting, and 96 have reached completion. 13 trials have been terminated or withdrawn. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. Across the portfolio, planned enrollment totals 216,341 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.

221
Total Trials
28
Recruiting
12
Other Active
96
Completed
13
Terminated / Withdrawn
216,341
Total Enrollment

Termination reasons: Other54% · Recruitment38% · Funding8%

Recent Terminations

  • NCT05168475 Phase PHASE2 Stopped Nov 2023
    Cogan Syndrome
    "NIHR withdrawal of funding"
  • NCT03038750 Stopped Jun 2023
    Cardiovascular Diseases
    "The delay due to suspending the study due to covid, subsequent problems in synthesis, supply and yield of BQ123, prevented completion of the study as planned."
  • NCT04021316 Phase NA Stopped Apr 2023
    Allograft
    "DMC noted that the primary end point of healed index ulcer at 12 weeks was reached only in 11.5%, whereas a higher figure of 42.5% had been used for the original power calculation, suggesting the trial is significantly underpowered."
  • NCT03994783 Phase PHASE3 Stopped Jan 2023
    Antibody-mediated Rejection
    "Stopped at start of COVID-19 pandemic - non-feasible"
  • NCT03043898 Stopped Apr 2020
    Asthma
    "COVID-19"
  • NCT03277209 Phase PHASE1 Stopped Dec 2019
    Pancreas Cancer
    "terminated due to slow accrual"
  • NCT02836353 Phase NA Stopped Mar 2019
    Dumping Syndrome
    "Reached scientific goals, further recruitment would not further advance the findings of study."
  • NCT01712945 Phase PHASE1/PHASE2 Stopped Oct 2017
    Multiple Sclerosis
    "interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab"
  • NCT02350426 Phase PHASE1 Stopped Oct 2016
    Arthritis, Rheumatoid
    "A decision to stop the study was made by the site and GSK project team based on pre-defined stopping criteria in the protocol"
  • NCT02404428 Phase NA Stopped Sep 2016
    Prostate Cancer
    "Problems with recruitment"

Active Trials (12 total)

Top Conditions

Top Locations